BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease 2025 Bucci et al.

[Jaybee00]

Abstract​

Teclistamab, a T-cell engager targeting B-cell maturation antigen, showed promise as a rescue therapy in 10 patients with refractory autoimmune diseases and led to clinical and serologic improvements in most patients.



Paywalled….full abstract??

https://www.nejm.org/doi/full/10.1056/NEJMc2506740

 

[Jaybee00]

Popular article

Myeloma Drug Performs Well in Autoimmune Diseases

Safety could be problematic, however

www.medpagetoday.com

 

[Jaybee00]

If anyone has access to the full article, am interested in finding out when the positive response began (how many weeks after the first injection). Thanks.

 

[Jaybee00]

Paper—doesn’t indicate how long from first injection to first clinical response/improvement.

 

[Jonathan Edwards]

If anyone has access to the full article, am interested in finding out when the positive response began (how many weeks after the first injection).

What was the reason for wondering?

For several of these diseases positive response onset may be pretty unascertainable. For scleroderma if there is any actual improvement it will probably reflect very slow tissue repair over months. For lupus you are looking for either blocking flares - where it is a matter of chance when a flare was going to be - or improvement in things like proteinuria from renal damage which again might take months to show. Thrombocytopenia is the one thing that tends to improve rapidly but that tends to get confounded by concurrent use of steroids.

I doubt that CD38 has any particular role in any of these classical autoimmune diseases, although I suppose it is conceivable.

 

[ryanc97]

This is more assuming LLPC is the problem not CD38. There is interest in trying Teclistamab for those with low Nk cells.

 

[Jaybee00]

Tecli basically kills plasma cells by a different mechanism without CD38 involvement—this is my understanding.

 

[Jonathan Edwards]

Tecli basically kills plasma cells by a different mechanism without CD38 involvement—this is my understanding.

yes, I had forgotten it is BCMA and CD3.

 

[Jaybee00]

What was the reason for wondering?

I wanted to see if the response timeline for tecli (BCMA) was similar to that of the CD-38 drugs like Daratumumab (~2 months).

 

[Jonathan Edwards]

I wanted to see if the response timeline for tecli (BCMA) was similar to that of the CD-38 drugs like Daratumumab (~2 months).

Fair enough, I am sure you are aware of the caveats.

 

[ryanc97]

So can anyone access the paper… sci hub is not working for it